



European Investment Bank (EIB)

Luxembourg, 22/12/2022

Environmental and Social Completion Sheet (ESCS)¹

Overview

Project Name: *INDIVUMED GLOBAL CANCER DATABASE (EGFF)*

Project Number: *20170662*

Country: *Germany*

Project Description: *Financing expenditures in the oncology Research, Development and Innovation programmes for 2018-2021 consisting of: (1) the expansion of the clinical network, the plasma biobank and the collection of third parties biospecimens and data outside the clinical network with the scope of diversification of patient subgroups and tumours; (2) enhancing the biological characterisation and classification of tissues with multiple clinical data points; (3) establishing a bioinformatics and artificial intelligence solution to understand phenotypic and clinical data.*

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The promoter's investments concerned research, development and innovation activities in the pharmaceutical and biotechnology sectors; said financing enabled the expansion of the promoter's biobank to create a global cancer database solution that aims to accelerate drug and diagnostic development. The project's activities are not listed in any of the annexes of the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Furthermore, the project is carried out in existing facilities which are already authorised for similar activities and volumes, and which do not require an Environmental Impact Assessment (EIA) according to the applicable EU Directives.

The promotor has implemented and maintains a Quality Management System, validated according to ISO 9001:2008 for the scope of collection of biological samples and clinical data (Biobank), research services in: immunohistochemistry, the analysis of signalling proteins, drug profiling and the establishment of primary cell culture and molecular biology.

The project is expected to lead to important social benefits stemming from its focus on the development of novel tools targeted to facilitate the discovery and implementation of treatments for diseases linked with high unmet medical and social needs, particularly in the field of oncology.

¹ The template is for ILs and FLs



European Investment Bank (EIB)

Luxembourg, 22/12/2022

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.